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Abstract
Organic anion transporting polypeptide (OATP) 1B1 mediates the hepatic uptake of many drugs 
including lipid-lowering statins. Decreased OATP1B1 transport activity is often associated with 
increased systemic exposure of statins and statin-induced myopathy. Antimalarial drug 
chloroquine (CQ) is also used for long-term treatment of rheumatoid arthritis and systemic lupus 
erythematosus. CQ is lysosomotropic and inhibits protein degradation in lysosomes. The current 
studies were designed to determine the effects of CQ on OATP1B1 protein degradation, 
OATP1B1-mediated transport in OATP1B1-overexpressing cell line, and statin uptake in human 
sandwich-cultured hepatocytes (SCH). Treatment with lysosome inhibitor CQ increased OATP1B1 
total protein levels in HEK293-OATP1B1 cells and in human SCH as determined by OATP1B1 
immunoblot. In HEK293-FLAG-tagged OATP1B1 stable cell line, co-immunofluorescence 
staining indicated that intracellular FLAG-OATP1B1 is colocalized with lysosomal associated 
membrane glycoprotein (LAMP)-2, a marker protein of late endosome/lysosome. Enlarged 
LAMP-2-positive vacuoles with FLAG-OATP1B1 protein retained inside were readily detected in 
CQ-treated cells, consistent with blocking lysosomal degradation of OATP1B1 by CQ. In 
HEK293-OATP1B1 cells, without pre-incubation, CQ concentrations up to 100 μM did not affect 
OATP1B1-mediated [3H]E217G accumulation. However, pre-incubation with CQ at clinically 
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relevant concentration(s) significantly decreased [3H]E217G and [3H]pitavastatin accumulation in 
HEK293-OATP1B1 cells and [3H]pitavastatin accumulation in human SCH. CQ pretreatment (25 
μM, 2 h) resulted in ∼1.9-fold decrease in Vmax without affecting Km of OATP1B1-mediated 
[3H]E217G transport in HEK293-OATP1B1 cells. Pretreatment with monensin and bafilomycin 
A1, which also have lysosome inhibition activity, significantly decreased OATP1B1-mediated 
transport in HEK293-OATP1B1 cells. Pharmacoepidemiologic studies using data from the U.S. 
Food and Drug Administration Adverse Event Reporting System indicated that CQ plus 
pitavastatin, rosuvastatin, and pravastatin, which are minimally metabolized by the cytochrome 
P450 enzymes, led to higher myopathy risk than these statins alone. In summary, the present 
studies report novel findings that lysosome is involved in degradation of OATP1B1 protein and 
that pre-incubation with lysosomotropic drug CQ downregulates OATP1B1 transport activity. Our 
in vitro data in combination with pharmacoepidemiologic studies support that CQ has potential to 
cause OATP-mediated drug–drug interactions.
Graphical abstract
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Introduction
Drug–drug interactions (DDIs), which often lead to adverse drug effects, are a major 
concern in patients receiving multidrug therapy.1 The organic anion-transporting 
polypeptides (OATPs) belong to the solute carrier organic anion (SLCO) transporter 
superfamily.2 OATP1B1 is predominantly expressed on the basolateral membranes of 
hepatocytes and mediates the hepatic uptake of many drugs such as HMG-CoA reductase 
inhibitor statins, rifampicin, and paclitaxel as well as endogenous compounds.3,4 Decreased 
transport activity of OATP1B1 due to genetic variation [e.g., the single nucleotide 
polymorphism (SNP) V174A of OATP1B1] and DDIs is often associated with increased 
systemic exposure of statins and statin-induced myopathy.5–7 OATP1B1 has been 
recognized as an important determinant of transporter-mediated DDIs.8
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Chloroquine (CQ), a 4-aminoquinoline class of drug, is a lysosomotropic agent that 
accumulates preferentially within the lysosome. It increases the intralysosomal pH,9 and 
inhibits lysosomal degradation of proteins including many transport proteins such as 
glutamate transporter10 and glucose transporter (GLUT) 1 and 2.11,12 The effect of CQ on 
OATP1B1 protein degradation has not been reported. CQ interacts with several transporters 
as substrate and/or inhibitor. CQ is a substrate and inhibitor of multidrug and toxin extrusion 
(MATE) 1.13 It also inhibits substrates transport mediated by P-glycoprotein (P-gp)14 breast 
cancer resistance protein (BCRP)14 and OATP1A2.15 In rat sandwich-cultured hepatocytes 
(SCH), pretreatment with 10 μM CQ for 48 h significantly decreased total accumulation of 
rosuvastatin in cells and bile canaliculi.16 Since rosuvastatin is a substrate of multiple 
transporters including OATP1B1,17 we hypothesize that CQ pretreatment may modulate the 
transport function of OATP1B1.
In addition to being used for treatment of malaria and amebic infection,18 CQ is also used 
for long-term treatment of rheumatoid arthritis and systemic lupus erythematosus.19–22 It is 
currently in clinical trials for cancer therapy either alone23–25 or in combination with 
chemotherapy drugs.26,27 Considering the widespread use of statins in cardiovascular 
diseases, concurrent administration of statins and CQ is likely. To the best of our knowledge, 
the effects of CQ on systemic exposure of statins and statin-associated myopathy have not 
been reported in clinical studies. The FDA Adverse Event Reporting System (FAERS) is a 
database that contains information on adverse events and medication error reports submitted 
to the FDA.28 This database is designed to support the FDA's postmarketing safety 
surveillance program for drug and therapeutic biologic products. The FAERS has been 
widely used for pharmacoepidemiologic studies including assessing statin-related myopathy 
risk due to DDIs.29,30 The current studies were designed to determine the effects of CQ on 
OATP1B1 protein degradation, OATP1B1-mediated transport in OATP1B1-overexpressing 
cell line, and statin uptake in human SCH. The myopathy risk was also compared in patients 
concomitantly taking CQ and statins vs statins alone using data from the FAERS.
The effects of CQ on OATP1B1 protein degradation and transport activity were determined 
in HEK293 stable cell lines overexpressing OATP1B1 (HEK293-OATP1B1) or FLAG-
tagged OATP1B1 (HEK293-FLAG-OATP1B1). Pitavastatin and estradiol 17β-D-glucuronide 
(E217G), which are sensitive OATP1B1 substrates for studying the inhibition of OATP1B1 
transport activity in vitro,31 were used as OATP1B1 probe substrates in HEK293-OATP1B1 
and -FLAG-OATP1B1 stable cell lines. The effect of CQ on hepatic uptake of therapeutic 
drug pitavastatin was also determined in the physiologically relevant human SCH model. 
Pitavastatin, pravastatin, and rosuvastatin are OATP1B1 substrates32 and are minimally 
metabolized by the cytochrome P450 enzymes.33–35 These three statins were selected in 
current pharmacoepidemiologic studies to determine whether CQ plus statins (pitavastatin, 
rosuvastatin, and pravastatin) leads to a higher risk for myopathy than these statins alone, 
using data from the FAERS.
Alam et al. Page 3
Mol Pharm. Author manuscript; available in PMC 2016 August 02.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Experimental Section
Materials
Estradiol 17β-D-glucuronide (E217G), chloroquine diphosphate, IGEPAL (NP-40), Hanks 
balanced salt solution (HBSS), dexamethasone, dimethyl sulfoxide (DMSO), Triton X-100, 
Dulbecco's modified Eagle medium (DMEM), fetal bovine serum (FBS), trypsin–EDTA 
solution, antibiotic antimycotic solution, Dulbecco's phosphate-buffered saline (DPBS), and 
bovine serum albumin (BSA) were purchased from Sigma-Aldrich (St. Louis, MO). 
Monensin sodium salt was purchased from Santa Cruz (Dallas, TX). Bafilomycin A1 was 
purchased from LC Laboratories (Woburn, MA). Insulin, minimum essential medium 
(MEM) nonessential amino acids (NEAA), L-glutamine, and penicillin–streptomycin were 
purchased from Life Technologies (Grand Island, NY). Matrigel and insulin/transferrin/
selenium (ITS+ premix) were purchased from BD Biosciences (Bedford, MA). Cultrex poly-
L-lysine was purchased from Trevigen, Inc. (Gaithersburg, MD). Geneticin was purchased 
from Life Technology (Grand Island, NY). Complete protease inhibitor cocktail tablets were 
purchased from Roche Diagnostics (Indianapolis, IN). [3H]Pitavastatin (specific activity 5 
Ci/mmol) and unlabeled pitavastatin were purchased from American Radiolabeled 
Chemicals (St. Louis, MO). [3H]E217G (specific activity 41.4 Ci/mmol) was purchased 
from PerkinElmer Life Science (Waltham, MA). Bio-Safe II liquid scintillation mixture was 
obtained from Research Products International (Mt. Prospect, IL). All other reagents were 
purchased from VWR International (Radnor, PA).
Estimation of Maximum Unbound Concentration of CQ at the Inlet to Liver
Maximum concentration of CQ at the inlet of the liver (Iin,max) was estimated according to 
eq 1, described previously.36
(1)
The values for the unbound fraction of CQ in the plasma (fu), absorption rate constant (ka), 
and hepatic blood flow (Qh) used in eq 1 are 0.45,18 0.1 min−1,37 and 1500 mL/min,38 
respectively. The maximum concentration of CQ in the systemic circulation (Cmax) and 
associated dose (D) were obtained from the literature and are summarized in Table 2. Since 
CQ has high bioavailability and almost complete absorption after oral administration,18 the 
fraction of CQ absorbed from the gastrointestinal tract intact (FaFg) was set at 1.18,39 
Unbound concentration of Iin,max (Iu,in,max) was calculated as fuIin,max.
Cell Culture
The human embryonic kidney (HEK) 293 stable cell line overexpressing OATP1B1 
(HEK293-OATP1B1) was provided by Dr. Dietrich Keppler.3 A HEK293 stable cell line 
overexpressing FLAG-tagged OATP1B1 (HEK293-FLAG-OATP1B1) was established by 
transfection of a mammalian plasmid expression vector encoding C-terminus FLAG-tagged 
OATP1B1 (pCMV6-FLAG-OATP1B1), which was custom constructed through Origene 
(Rockville, MD). Both cell lines were maintained in DMEM medium containing 10% FBS, 
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1% antibiotic and antimycotic solution, and 600 μg/mL Geneticin (Life Technologies, Grand 
Island, NY). Cells were cultured in a humidified atmosphere (95% O2, 5% CO2) at 37 °C.
Human Sandwich-Cultured Hepatocytes (SCH)
Human hepatocytes were purchased from Triangle Research Laboratories, LLC (Research 
Triangle Park, NC). Demographics of the donors are listed in Table 1. Human SCH were 
cultured as described previously.40 In brief, on day 0, cells were plated at 3.5 × 105 cells per 
well in 24-well Biocoat culture plates in phenol red free DMEM containing 5% (v/v) FBS, 
1% (v/v) MEM NEAA, 2 mM L-glutamine, 100 units of penicillin G sodium/mL, 100 g/mL 
of streptomycin sulfate, 1 μM dexamethasone, and 4 μg/mL insulin. Cells were cultured at 
37 °C in a humidified incubator (95% O2, 5% CO2). At 6 h after seeding, when the cells 
were attached to the plate, cells were overlaid with Matrigel at a final concentration of 0.25 
mg/mL in phenol red free DMEM supplemented with 2 mM L-glutamine, 1% (v/v) MEM 
NEAA, 100 units/mL of penicillin G sodium, 100 g/mL of streptomycin sulfate, 0.1 μM 
dexamethasone, and 1% (v/v) ITS+ premix. Culture medium was replaced every 24 h. 
Uptake experiments were conducted on day 2 of culture.
Immunoblotting
Immunoblotting was conducted similarly to those described previously.41 In brief, cells were 
seeded at a density of 1.1 × 105 cells per well in 24-well culture plates precoated with poly-
L-lysine and cultured for 48 h. Two cell lysis methods (with or without trypsinization) were 
compared to optimize the OATP1B1 immunoblot. After aspirating culture media and rinsing 
once with DPBS, whole cell lysates (WCL) were prepared by adding ice cold lysis buffer, 
which contained 50 mM Tris/HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% (v/v) NP-40, 
0.5% Na-deoxycholate, and Complete protease inhibitor cocktail (Roche Diagnostics, 
Indianapolis, IN), either directly onto the cells in culture plate (without trypsinization) or to 
cell pellets collected after trypsinization with 1× Trypsin/EDTA (Sigma-Aldrich, St. Louis, 
MO) and subsequent washing with DPBS (with trypsinization). Whole cell lysates (WCL) 
(50 μg) were resolved on 10% SDS–PAGE (Bio-Rad, Hercules, CA). Proteins were then 
transferred to nitrocellulose membranes and subsequently probed with the following primary 
antibodies: rabbit polyclonal OATP1B1 antibody (Fisher Scientific Company, LLC, Denver, 
CO) custom-generated according to a previous publication (1:1000 dilution),43 rabbit 
polyclonal anti-FLAG antibody (1:4000 dilution) and mouse monoclonal anti-β-actin 
antibody (1:5000 dilution) (Sigma-Aldrich, St. Louis, MO), mouse monoclonal anti-
GAPDH antibody (1:2000) (Santa Cruz Biotechnology, Inc., Dallas, TX), and anti-alpha 1 
sodium potassium ATPase antibody (1:8000 dilution) (Abcam, Cambridge, MA). After 
incubation with HRP-conjugated secondary antibody (Santa Cruz Biotechnology, Inc., 
Dallas, TX), signals were detected by Supersignal West Duro (Pierce, Rockford, IL) using a 
Bio-Rad ChemiDoc XRS imaging system (Bio-Rad Laboratories, Hercules, CA). Image Lab 
v4.1 software (Bio-Rad Laboratories, Hercules, CA) was used to perform the densitometry 
analysis.
Immunofluorescence Staining
Experiments were conducted similarly to those published previously, with slight 
modifications.44 In brief, HEK293-FLAG-OATP1B1 cells were grown to confluence on 
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poly-L-lysine coated coverslips in 24-well plates. Cells were fixed for 20 min with methanol, 
permeabilized with Triton X-100 (0.25%) in DPBS for 10 min at room temperature, and 
blocked with 5% BSA in DPBS for 1 h at room temperature. For co-immunofluorescence 
staining of FLAG-OATP1B1 and LAMP-2, cells were co-incubated with the rabbit 
polyclonal anti-FLAG antibody (Sigma-Aldrich, St. Louis, MO, 1:100 dilution) and mouse 
monoclonal antibody of LAMP-2 (Clone H4B4, Santa Cruz Biotechnology, Inc., Dallas, TX, 
1:50 dilution) at 37 °C for 2 h. After washing 3 times with DPBS, cells were co-incubated 
with secondary antibodies Alexa Fluor 488-conjugated goat anti-mouse IgG (Life 
Technologies, Grand Island, NY, 1:200 dilution) and Alexa Fluor 594-conjugated goat anti-
rabbit IgG (Life technologies, Grand Island, NY, 1:200 dilution) at 37 °C for 1 h. Both 
primary and secondary antibodies were diluted in DPBS containing 5% BSA. Diamidino-2-
phenylindole (DAPI) (300 nM) was used for counterstaining nuclei. After washing, the 
coverslips were mounted on glass slides with ProLong gold antifade reagent (Life 
Technologies, Grand Island, NY). Images were taken using Leica SP2 MP (Leica 
Microsystems, Inc., Buffalo Grove, IL) or Olympus FV1000 (Olympus Scientific Solutions 
Americas Corp., Waltham, MA) confocal microscopes as indicated in the figure legends.
Transport Studies
Transport studies in HEK293 stable cell lines and in human SCH were conducted similarly 
to those described previously.41,42 HEK293-OATP1B1, -FLAG-OATP1B1, and -Mock cells 
were seeded at a density of 0.8–1.1 × 105 cells/well in 24-well culture plates precoated with 
poly-L-lysine and were cultured for 48–72 h. Cells from stable cell lines or human SCH were 
either pretreated with culture medium containing CQ, monensin, bafilomycin A1, or vehicle 
control for the designated times or not pretreated. 0.1% DMSO was used as vehicle control 
for monensin and bafilomycin A1 treatment. As CQ stock (50 mM) was resolved in water, 
CQ-free fresh medium was used as vehicle control for CQ pretreatment. To determine the 
effects of CQ on OATP1B1-mediated transport after prolonged treatment, HEK293-
OATP1B1 cells were preincubated with CQ-free (CTL) or 25 μM CQ-containing medium 
for 2 h. At the end of pre-incubation, the culture medium was aspirated and CTL cells were 
cultured in CQ-free medium and cells pretreated with 25 μM CQ were cultured in medium 
containing 1.5 μM CQ, for the indicated time, up to 24 h.
At the time of uptake experiments, after rinsing with prewarmed (37 °C) HBSS buffer (pH 
7.4) three times, cells were incubated with HBSS containing [3H]E217G (1 μM, 2 min) or 
[3H]pitavastatin (1 μM, 0.5 min) in the absence or presence of testing drugs (CQ or 
rifampicin). At the end of incubation, the buffer was aspirated rapidly, and the cells were 
rinsed with ice-cold HBSS three times and then lysed with Triton X-100 (0.5% v/v) in 
DPBS. An aliquot of the lysate was subjected to liquid scintillation counting (LS6500 
scintillation counter, Beckman Coulter, Brea, CA). Substrate accumulation was normalized 
to protein concentration determined by BCA assay (Pierce Chemical, Rockford, IL) and 
corrected for nonspecific binding of the substrate by including a non-overlaid poly-L-lysine 
coated blank plate for uptake studies in stable cell lines and a Matrigel overlaid blank plate 
for human SCH, respectively.
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To determine [3H]E217G transport kinetic parameters, the maximal transport velocity 
(Vmax) and the affinity constant (Km), [3H]E217G accumulation (0.1–40 μM, 2 min) was 
determined in HEK293-OATP1B1 and -Mock cells following pretreatment with CQ(25 μM) 
or CTL. Values of [3H]E217G accumulation in Mock cells were subtracted from those in 
HEK293-OATP1B1 cells. The Vmax and Km values of E217G transport were estimated by 
fitting the Michaelis–Menten equation (eq 2) to the data using Phoenix WinNonlin, v6.3 
(Certara, St. Louis, MO), where ν is E217G transport velocity and S is E217G concentration.
(2)
Lactate Dehydrogenase (LDH) Cytotoxicity Assay
Experiments were conducted similarly to those published previously.45 After treatment with 
CQ, monensin, bafilomycin A1, or respective vehicle control, cell culture medium was 
assayed for LDH activity with a cytotoxicity detection kit (Roche Diagnostics GmbH, 
Mannheim, Germany), according to the manufacturer's instructions. Triton X (2%) treated 
and non-treated cells served as the 100% cytotoxicity positive control and negative control, 
respectively.
Pharmacoepidemiologic Studies Using the FDA Adverse Event Reporting System (FAERS)
Studies using the FAERS database were similar to those published previously.29 All of the 
adverse event case reports from quarter 1 of 2004 to quarter 3 of 2012 were used for data 
analysis (n = 6.47 millions). The myopathy adverse event was defined as published 
previously.29 It includes all the mild or severe myopathy symptoms. The drug names and 
their synonyms were mapped based on their DrugBank46 drug names. Our drug interaction 
hypothesis was whether CQ plus statins (pitavastatin, rosuvastatin, and pravastatin) leads to 
higher myopathy risk than these statins alone. A similar hypothesis was posed to test the 
interactions between sulfonylureas and statins in our previous work.47 The interaction 
between CQ and statins was further tested in different subpopulations defined by age and 
gender.
Data Analysis
For the statistical analysis in Figures 4, 5, 6 and 7B, fold changes and associated standard 
errors (SEs) were estimated by generalized linear mixed models with the log link function, a 
fixed effect (treatment time or group), and a random effect (experiment date or hepatocyte 
donor), adjusting for treatment time/group-specific overdispersion. In the case of multiple 
comparisons, p-values were adjusted based on Bonferroni's method. The Chi-square test and 
Student's t test were used for statistical analysis in Table 3 and the Figure 8 inset, 
respectively. A two-sided p-value of <0.05 defines statistical significance. SAS software 
(version 9.3, Cary, NC) was used for statistical analyses.
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Results
Estimation of the Maximum Unbound CQ Concentration at the Inlet to the Liver
The Iu,in,max of CQ was estimated to be 18.3–23.4, 28.2, and 56.8 μM based on data in 
rheumatoid arthritis patients chronically treated with CQ at a daily dose of 191 mg48 and 
after a 300 and 600 mg single dose of CQ in healthy volunteers,39,49 respectively (Table 2). 
CQ concentrations of 2.5–25 μM, which are clinically relevant, were used in subsequent 
experiments.
CQ Treatment Increased Total Protein Levels of OATP1B1 in HEK293-OATP1B1 Cells and in 
Human SCH
Initially, we tested the specificity of our custom-generated OATP1B1 antibody and 
optimized OATP1B1 immunoblot protocol by comparing two cell lysis methods, directly 
lysing the cells in the culture plate without trypsinization and lysing the cell pellets collected 
after trypsinization. As shown in Figure 1, OATP1B1 antibody specifically detected 
OATP1B1 in HEK293-OATP1B1 stable cell line but not in negative control HEK293-Mock 
(Mock) cells in whole cell lysates prepared with both methods. In cells that were lysed 
directly in the culture plates without trypsinization, the molecular weight of OATP1B1 
detected by the OATP1B1 antibody was ∼90 kDa. A lower molecular weight band of 
OATP1B1 (∼64 kDa) was prominent in cell lysates prepared from trypsinized HEK293-
OATP1B1 cells, while this band was negligible in cells lysed directly without trypsinization. 
Since the molecular weight of OATP1B1 (∼90 kDa) that resulted from the direct lysis 
method is similar to that published previously,3 this method was used to prepare whole cell 
lysates for immunoblot in subsequent experiments.
To determine the involvement of lysosome in degradation of OATP1B1, total protein levels 
of OATP1B1 were compared in HEK293-OATP1B1 cells treated with CQ or CTL by 
OATP1B1 immunoblotting. Treatment with 25 μM CQ for 2 and 5 h and 100 μM CQ for 5 h 
increased OATP1B1 total protein levels to 1.2 ± 0.1, 1.5 ± 0.1 and 1.5 ± 0.3 fold of control, 
respectively (Figure 2A).
Increased total protein levels of Na,K-ATPase following lysosome inhibition by CQ 
treatment were reported previously.50 In the current studies, we used Na,K-ATPase as a 
positive control for increased total protein levels following lysosome inhibition. As shown in 
Figure 2B, treatment with CQ (25 μM) for 2 and 5 h increased Na,K-ATPase total protein 
levels to 1.2 ± 0.1 and 1.4 ± 0.2 fold of control, respectively.
Total protein levels of endogenous OATP1B1 were also compared in human SCH treated 
with CQ or vehicle control. As shown in Figure 2C, treatment with 10 μM CQ for 5 h 
increased OATP1B1 protein levels to 1.7 ± 0.5 fold of control in human SCH (ranging from 
1.2–2.1-fold of control, n = 3 donors). In human SCH, a major OATP1B1 band at ∼64 kDa 
was observed (Figure 2C), similar as published previously.51
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Colocalization of Intracellular FLAG-OATP1B1 with LAMP-2 in HEK293-FLAG-OATP1B1 
Stable Cell Line
olocalization of OATP1B1 with LAMP-2, a late endosome/lysosome marker protein,52 was 
determined by immunofluorescence staining. Since our custom-generated OATP1B1 
antibody is not suitable for immunofluorescence staining (data not shown), a stable cell line 
overexpressing FLAG-tagged OATP1B1 was established in HEK293 cells to overcome this 
limitation. Expression and transport function of FLAG-OATP1B1 in HEK293-FLAG-
OATP1B1 cells were confirmed by immunoblotting and [3H]E217G accumulation, 
respectively. Both OATP1B1 and FLAG antibodies specifically detected the FLAG-tagged 
OATP1B1 in HEK293-FLAG-OATP1B1 cells, but not in the negative control HEK293-
Mock cells (Figure S1A). The [3H]E217G accumulation (1 μM, 2 min) in HEK293-FLAG-
OATP1B1 cells was ∼70-fold higher than in the HEK293-Mock cells (Figure S1B).
FLAG immunofluorescence staining showed specific staining in HEK293-FLAG-OATP1B1 
cells but not in HEK293-Mock cells (data not shown). In both CQ-treated and vehicle 
control treated cells, in addition to the plasma membrane localization of FLAG-OATP1B1, 
intracellular localization of FLAG-OATP1B1 was also observed, which had a punctuated 
staining pattern reminiscent of vesicular compartments (Figure 3G–O, red). Some 
intracellular FLAG-OATP1B1 was detected in LAMP-2 positive vacuoles and colocalized 
with LAMP-2 (Figure 3J–O, as indicated by arrows and yellow coloring in merged images). 
Enlarged LAMP-2-positive vacuoles with FLAG-OATP1B1 protein retained inside were 
readily detected in cells treated with 25 μM CQ (Figure 3K,L,N,O) and 100 μM CQ (Figure 
S2H), consistent with inhibition of lysosomal degradation of FLAG-OATP1B1 by CQ.
Pretreatment Effects and Direct Inhibition of CQ on OATP1B1-Mediated Transport
To determine the pretreatment effects of CQ on OATP1B1-mediated transport, HEK293-
OATP1B1 or -FLAG-OATP1B1 was preincubated with CQ or vehicle CTL at indicated 
concentrations for 0.5–5 h. After washing, accumulation of [3H]E217G (1 μM, 2 min) or 
[3H]pitavastatin (1 μM, 0.5 min) was determined in the absence of CQ (Figure 4A–C, pre-
incubation). In HEK293-OATP1B1 cells, at all CQ concentrations (2.5–100 μM) and time 
points determined (0.5–5 h), pretreatment with CQ significantly decreased [3H]E217G 
accumulation (all p < 0.001 vs control, Figure 4A). CQ pretreatment (10 and 25 μM) for 
0.5–5 h also significantly decreased [3H]pitavastatin accumulation (all p < 0.001 vs control, 
Figure 4B). In HEK293-FLAG-OATP1B1 cells, [3H]E217G accumulation was significantly 
decreased following pre-incubation with CQ (10–100 μM) for 0.5–5 h (all p < 0.05 vs 
control, Figure 4C).
To determine the direct interaction of CQ on OATP1B1-mediated transport, experiments 
were conducted in HEK293-OATP1B1 cells without CQ pre-incubation. [3H]E217G 
accumulation (1 μM, 2 min) was determined in the presence of CQ at indicated 
concentrations, vehicle CTL, or positive control rifampicin (Figure 4D, co-incubation). As 
shown in Figure 4D, co-incubation with 25 μM rifampicin, a potent inhibitor of OATP1B1,53 
significantly decreased [3H]E217G accumulation to 0.02 ± 0.021 fold of control (adjusted p 
< 0.01). However, there is no significant difference in [3H]E217G accumulation in the 
presence of CQ (5–100 μM) vs CLT (all adjusted p > 0.05).
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The effect of CQ on OATP1B1-mediated [3H]E217G accumulation was further compared 
between two scenarios, a pre+co-incubation scenario, when [3H]E217G accumulation (1 
μM, 2 min) was determined in the presence of 100 μM CQ after pre-incubation with CQ 
(100 μM, 5 h), and a co-incubation scenario as described above. For comparison purposes, 
100 μM CQ co-incubation data in Figure 4D was replotted in Figure 4E. Under pre+co-
incubation conditions, [3H]E217G accumulation decreased to 0.432 ± 0.02 fold compared to 
values measured under the co-incubation condition (p < 0.001, Figure 4E). The LDH assay 
showed negligible toxicity after 5 h treatment with 100 μM CQ in HEK293-OATP1B1 cells 
(Figure S3A).
Effects of Monensin and Bafilomycin A1 on OATP1B1-Mediated Transport
Three classes of compounds are frequently used to elevate the pH in endosome and other 
acidic organelles, which include lysosomotropic weak bases (e.g., chloroquine54), 
carboxylic ionophores (e.g., monensin55), and inhibitors of vacuolar H+-ATPase (e.g., 
bafilomycin A156) (reviewed by Huotari57). In addition to CQ, monensin and bafilomycin 
A1 are also reported to inhibit endosome–lysosome system acidification and lysosome 
activity.58,59 We determined whether pretreatment with monensin or bafilomycin A1 also 
affects OATP1B1-mediated [3H]E217G accumulation (1 μM, 2 min) in HEK293-OATP1B1 
cells. Pretreatment with monensin (5 μM) for 0.5–2 h significantly decreased [3H]E217G 
accumulation ranging from 0.356 ± 0.036 to 0.512 ± 0.047 fold of CTL (all p < 0.0001 vs. 
CTL) (Figure 5A). Pretreatment with bafelomycin A1 (0.5 μM) for 1 and 5 h significantly 
decreased [3H]E217G accumulation to 0.60 ± 0.083 to 0.40 ± 0.19 fold of CTL, respectively 
(all p < 0.01 vs. CTL) (Figure 5B). The LDH assay showed negligible toxicity after 
monensin and bafilomycin A1 treatment in HEK293-OATP1B1 cells (Figure S3A).
Effects of CQ on OATP1B1-Mediated Transport after Prolonged Treatment
CQ is administered daily for long-term treatment of rheumatoid arthritis and lupus.22 In 
patients who had been taking CQ for at least six months, the dose normalized average 
unbound steady state concentration (Css) of CQ is ∼1.7 μM.48 The effect of CQ on 
OATP1B1-mediated transport after prolonged treatment was determined in HEK293-
OATP1B1 cells. After 2 h treatment with CQ-free medium or medium containing 25 μM 
CQ, cells were subsequently cultured in CQ-free medium or 1.5 μM CQ-containing medium, 
respectively. Values of [3H]E217G accumulation in CQ-treated cells were compared to CQ-
free treatment (CTL) at indicated times. A similar trend as in Figure 4A, CQ pretreatment 
(25 μM, 2 h) significantly decreased [3H]E217G accumulation to 0.373 ± 0.014 fold of 
control (Figure 6, 0 h). At each time point of 6, 18, and 24 h, [3H]E217G accumulation in 
1.5 μM CQ-containing medium was significantly decreased compared to CTL (all p < 
0.0001 vs CTL) (Figure 6). The LDH assay showed negligible toxicity following 24 h 
incubation with 1.5 μM containing medium in HEK293-OATP1B1 cells pretreated with 
CQ(25 μM, 2 h) (Figure S3B).
Pretreatment with CQ Significantly Decreased [3H]-Pitavastatin Accumulation in Human 
SCH
The effects of CQ on OATP1B1 transport function was further determined in the 
physiologically relevant human SCH model with [3H]pitavastatin60 as a probe substrate. 
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[3H]Pitavastatin (1 μM) accumulation in human SCH was linear at least up to 5 min (Figure 
7A). An incubation time of 0.5 min was used for subsequent uptake experiments in human 
SCH. Pretreatment with CQ (10 μM, 5 h) significantly decreased [3H]pitavastatin 
accumulation to 0.65 ± 0.084 fold of control (p < 0.01 vs control, Figure 7B). The LDH 
assay showed negligible toxicity after 5 h treatment with CQ at 10 μM (Figure S3C).
DDIs Associated with Increased Risk of Myopathy
To determine whether CQ plus statins (rosuvastatin, pravastatin, and pitavastatin) leads to 
higher myopathy risk than these statins alone, pharmacoepidemiological studies were 
conducted using data from the FAERS database. As shown in Table 3, among all patient 
data, CQ plus statins led to 17.2% myopathy risk compared to statins alone, 9.2%. The 
relative risk (RR) is 1.87 with a p-value of 0.05. It has been reported that the female gender 
and advanced age are associated with higher risk for myopathy.61 Therefore, the interaction 
effect between CQ and statins was further analyzed within the subpopulations. The only sub-
population that showed significant CQ and statin DDIs was women. In women, CQ plus 
statins significantly increased the myopathy risk from 9.6% to 21.9% (Relative Risk = 2.28, 
p < 0.05 vs. statins alone). In other subpopulation analyses, men, >50 years, and <50 years, 
the CQ plus statins all showed increased myopathy risk, but were not statistically significant.
Effects of CQ on Transport Kinetics of [3H]E217G in HEK293-OATP1B1 Cells
As shown in Figure 8, CQ pretreatment (25 μM, 2 h) significantly decreased the maximum 
rate of [3H]E217G uptake (Vmax) values compared to vehicle CTL treatment (57.15 ± 7.65 
vs 30.38 ± 5.22 pmol/mg protein/min, p < 0.05), without affecting the Km values (7.20 
± 0.57 vs 6.30 ± 0.70 μM).
Discussion
Understanding the mechanism(s) underlying altered transport activity of OATP1B1 has 
significant relevance in predicting potential OATP1B1-mediated DDIs. The current study 
demonstrates that the lysosome pathway is involved in degradation of OATP1B1, and that 
pre-incubation with lysosomotropic drug CQ downregulates OATP1B1-mediated transport. 
Pharmacoepidemiologic studies using data from the FAERS indicated that CQ plus statins 
(pitavastatin, rosuvastatin, and pravastatin) led to a greater myopathy risk than these statins 
alone.
Plasma membrane proteins are constitutively subjected to endocytosis.57 A portion of the 
internalized cargo is transported via late endosome for degradation by lysosomes.57 
Treatment with CQ increased the total protein levels of OATP1B1 expressed exogenously in 
HEK293-OATP1B1 cells and endogenously in human SCH (Figure 2A,C). Increased total 
protein levels of membrane proteins following CQ treatment was reported previously for 
bone morphogenic protein type II receptor (BMPR-II),62 the transmembrane protein β-site 
amyloid precursor protein cleaving enzyme (BACE),63 and Na,K-ATPase.50 Increased 
Na,K-ATPase total protein levels following CQ treatment was also detected in current 
studies (Figure 2B), consistent with previous report.50 Plasma membrane localization of 
OATP1B1 has been detected by immunofluorescence staining in several reports.3,53,64 
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However, association of intracellular OATP1B1 with subcellular organelles has not been 
reported. Current studies demonstrated that, in addition to plasma membrane localization, 
the intracellular FLAG-OATP1B1 proteins were localized to LAMP-2 positive late 
endosomes/lysosomes in HEK293-FLAG-OATP1B1 cells without CQ treatment and under 
lysosome inhibition following CQ treatment (Figure 3 and Figure S2 merged images). 
Overall, increased total protein levels of OATP1B1 upon CQ treatment and localization of 
OATP1B1 with LAMP-2 suggest that the lysosome pathway is involved in the degradation 
of OATP1B1 proteins.65
In the current studies, we focused on determining whether clinically relevant concentrations 
of CQ affect OATP1B1 transport activity and statin uptake in human SCH. The estimated 
Iu,in,max of CQ is 18.3–56.8 μM (Table 2). The unbound Css of CQ in the plasma is ∼1.7 μM 
in rheumatoid arthritis patients treated with CQ daily for long-term.48 In HEK293-
OATP1B1 cells, pretreatment with CQ at clinically relevant concentrations (2.5–25 μM) 
significantly decreased OATP1B1-mediated transport of [3H]E217G (Figure 4A,C) and 
[3H]pitavastatin (1 μM, 0.5 min) (Figure 4 B). CQ pretreatment (10 μM, 5 h) also 
significantly decreased [3H]pitavastatin accumulation (1 μM, 0.5 min) in human SCH 
(Figure 7B). Additionally, in HEK293-OATP1B1 cells preincubated for 2 h with 25 μM CQ 
(a concentration relevant to the Iu,in,max of CQ), and subsequently treated for up to 24 h with 
1.5 μM CQ (a concentration relevant to the unbound Css of CQ), values of [3H]E217G 
accumulation were significantly less than those in the CQ-free treatment CTL (Figure 6). 
These findings suggest that pretreatment with CQ at clinically relevant concentrations can 
downregulate OATP1B1-mediated transport in OATP1B1-overexpressing cell lines and 
accumulation of pitavastatin in human SCH. Pitavastatin is a substrate of multiple OATP 
transporters, including OATP1B1, 1B3, and 2B1.60,66 Currently, there is no known specific 
probe substrate or inhibitor of OATP1B1 available. This is a technical challenge to 
specifically study the transport function of endogenous OATP1B1 in primary human 
hepatocytes. Therefore, from our current study, we cannot draw a conclusion regarding 
whether transport function of endogenous OATP1B1 is downregulated by CQ in human 
SCH. The current study does not exclude the possibility that CQ may affect transport 
activity of other transporters in human SCH. Decreased pitavastatin accumulation in human 
SCH following CQ pretreatment (10 μM, 5 h) may represent a net effect of CQ on hepatic 
transport of pitavastatin. Further studies are warranted to determine whether other OATP 
transporters, including the closely related family member OATP1B3, can also be regulated 
by CQ.
The inhibitory effects of CQ toward OATP1B1 transport activity at clinically relevant 
concentrations led to our hypothesis that concurrent use of CQ and statins may have a higher 
myopathy risk than statins alone in patients. Pharmacoepidemiologic studies using data from 
the FAERS was utilized to test our hypothesis. Since CQ is a substrate and inhibitor of 
multiple CYP enzymes,67,68 to minimize potential CYP450 mediated DDIs, we selected 
three statins, pitavastatin, rosuvastatin, and pravastatin, which are minimally metabolized 
through CYP450 enzymes,34,35,69 in our pharmacoepidemiologic studies. Increased 
systemic exposure of these statins has been reported in subjects bearing the V174A 
polymorphism of OATP1B1 (reviewed by Niemi32). Our data indicated that CQ plus these 
three statins is associated with increased risk of myopathy compared to these statins alone 
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(Table 3). This result is consistent with the in vitro inhibitory effects of CQ toward 
OATP1B1-mediated transport and pitavastatin accumulation in human SCH following 
pretreatment at clinically relevant concentrations. Taken together, combination of our data 
from in vitro and pharmacoepidemiologic studies supports that potential OATP-mediated 
DDIs caused by CQ are likely.
A higher myopathy risk in women than men was observed in both the statins alone group 
and the CQ plus statins group (Table 3). The relative risk of myopathy (CQ plus statins vs 
statins alone) reaches a statistically significant level only in women, but not in men (Table 
3). These findings are consistent with what we have observed in the medical record 
database76 and reports from others61,77 that females have higher risk for myopathy than 
males. Smaller vascular volumes and reduced muscle mass in females, which may result in 
greater tissue drug exposure per statin dose, are possible reasons of higher myopathy risk in 
women.61 Higher systemic exposure of statins in women was observed for pitavastatin,78 
while there is no gender difference in systemic exposure of pravastatin.79 For rosuvastatin, 
one study reported higher AUC and Cmax in women than in men,80 while no gender 
difference was observed for rosuvastatin pharmacokinetics in another study.81 The gender 
difference in pharmacokinetics of CQ and the effects of CQ on pharmacokinetics of statins 
have not been reported. A clinical DDI study determining the effects of CQ on systemic 
exposure of statins in women and men may help to elucidate the potential mechanism 
underlying the higher myopathy risk in patients in whom CQ and statins are administered 
concurrently compared with statins alone.
Recently, the effects of pretreatment on OATP1B1-mediated transport were reported for 
several OATP1B1 inhibitors. Pretreatment with cyclosporine,70 saquinavir, ritonavir,71 
simeprevir, asunaprevir, or daclatasvir72 significantly decreases OATP1B1-mediated 
transport. Pretreatment with cyclosporine decreased the apparent IC50 values toward 
OATP1B1 inhibition.31,73 In current studies, without CQ pre-incubation, CQ at 
concentrations 5–100 μM did not affect [3H]E217G accumulation (1 μM, 2 min) in 
HEK293-OATP1B1 cells (Figure 4D). This result is consistent with a recent report that 10 
μM CQ did not affect OATP1B1-mediated estrone-3-sulfate transport.15 However, when 
[3H]E217G accumulation was determined in the presence of CQ following CQ pre-
incubation, CQ, an apparent non-inhibitor of OATP1B1 determined without pre-incubation 
(Figure 4D), significantly decreased OATP1B1-mediated transport (Figure 4E). The current 
study reports a novel inhibitory effect of lysosomotropic drug CQ toward OATP1B1-
mediated transport, where an apparent noninhibitor CQ “gained” its inhibitory effect toward 
OATP1B1 after pre-incubation. In clinical conditions, a perpetrator drug may be 
administered prior to the victim drug. A perpetrator drug and a victim drug may coexist in 
the body for a period of time that is longer than the in vitro incubation time used to 
determine the perpetrator/substrate interaction (a few minutes in many cases). Our results 
together with others31,73,74 highlight the importance of introducing a pre-incubation step 
when assessing the OATP1B1-mediated DDI potential of an investigational drug in vitro. 
The current approach of using the OATP1B1 inhibition tree and R-value to assess OATP-
mediated DDIs in vitro assumes competitive transporter inhibition by investigational 
drugs.75 Our data support that mechanism(s) other than competitive inhibition of OATP1B1 
transport activity may also be important in causing OATP1B1-mediated DDIs.
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The finding that CQ pretreatment increased total OATP1B1 protein levels, but decreased 
OATP1B1 transport activity, may seem paradoxical at first. However, transporter function is 
not always correlated with the total protein levels of the transporters. For example, following 
PKC activation, the total protein levels of OATP1B3,41 OATP1A2,82 and OAT1 and 
OAT483,84 were not affected while their transport function was significantly decreased. CQ 
pretreatment decreased Vmax without affecting the Km values of OATP1B1-mediated 
[3H]E217G transport (Figure 8). A similar trend of decreased Vmax and unaffected Km was 
reported for OATP1A282 and OAT1,3 and 4,83–85 dopamine transporter,86 and sodium-
glucose transporter (SGLT1)87 upon PKC activation. In these previous studies, the decreased 
Vmax of substrate transport was associated with decreased surface levels for OATP1A2,82 
OAT1, 3 and 4,83–85 increased phosphorylation for dopamine transporter,86 or decreased 
turnover rate but unaltered surface levels for SGLT1.87 CQ has been reported to affect cell 
surface levels of several plasma membrane proteins such as the tumor necrosis factor 
receptor (TNF-R),88 the α-macroglobulin-protease (αM-P) surface receptors,89 and BMPR-
II.62 Short-term treatment with monensin and bafilomycin A1, which have lysosome 
inhibition activity, also resulted in significantly decreased OATP1B1-mediated transport 
(Figure 5). In addition to inhibiting lysosomal activity, CQ, monensin, and bafilomycin A1 
have other effects such as affecting trafficking of the membrane protein.90 The exact 
mechanism(s) through which CQ, monensin, and bafilomycin A1 downregulate transport 
function of OATP1B1 remain unknown and warrant further investigation.
In conclusion, the present studies report novel findings that CQ inhibits lysosome 
degradation of OATP1B1 protein; pre-incubation with CQ downregulates OATP1B1-
mediated transport in stable cell lines, and decreases pitavastatin uptake in human SCH. Our 
in vitro data in combination with pharmacoepidemiologic studies support that CQ has 
potential to cause OATP-mediated DDIs.
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Abbreviations Used
E217G estradiol 17β-D-glucuronide
ABC ATP-binding cassette
DDIs drug–drug interactions
HBSS Hanks balanced salt solution
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DMEM Dulbecco's modified Eagle medium
BSA bovine serum albumin
MEM minimum essential medium
NEAA nonessential amino acids
DPBS Dulbecco's phosphate-buffered saline
HEK293 human embryonic kidney 293
LDH lactate dehydrogenase
OATP organic anion transporting polypeptide
OATs organic anion transporters
SLCO solute carrier organic anion
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Figure 1. 
Characterization of OATP1B1 antibody and optimization of OATP1B1 immunoblot 
protocol. HEK293-OATP1B1 and -Mock cells were seeded at 1.1 × 105 cells/well in 24-well 
plates and cultured for 48 h prior to being harvested for immunoblot. Whole cell lysates 
(WCL) of HEK293-OATP1B1 cells were prepared either by adding ice-cold lysis buffer 
directly onto the culture plate after aspirating culture medium without trypsinization or by 
lysing the cells after trypsinization and subsequent washing. Immunoblot of OATP1B1 was 
performed with the custom-generated OATP1B1 antibody. GAPDH was used as the loading 
control. Representative images from n = 3 experiments are shown.
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Figure 2. 
Effects of CQ on total protein levels of OATP1B1 and Na,K-ATPase in HEK293-OATP1B1 
cells and on OATP1B1 total protein levels in human SCH. HEK293-OATP1B1 cells were 
seeded in 24-well plates at 1.1 × 105 cells/well, and were cultured for 48 h prior to 
treatment. Human SCH were cultured as described in the Experimental Section. WCL was 
prepared by directly lysing the cells in the culture plate without trypsinization. 
Representative immunoblot images of OATP1B1 (A) and Na,K-ATPase (B) in WCL of 
HEK293-OATP1B1 pretreated with CQ (25 or 100 μM) or CTL for indicated times are 
shown. GAPDH were used as the loading control for A and B. OATP1B1 and Na,K-ATPase 
protein levels determined by densitometry were normalized to levels of GAPDH. Fold 
changes of total protein levels of OATP1B1 in A and Na,K-ATPase in B (CQ vs CTL) are 
expressed as mean ± SD (n = 4 for both A and B). (C) Immunoblot of OATP1B1 and β-actin 
in WCL of human SCH pretreated with CQ (10 μM) or CTL for 5 h. OATP1B1 protein 
levels determined by densitometry were normalized to levels of β-actin. Fold changes of 
total protein levels of OATP1B1 (CQ vs CTL) are expressed as mean ± SD of n = 3 donor 
hepatocytes. Representative images are shown.
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Figure 3. 
Colocalization of FLAG-OATP1B1 and LAMP-2 in HEK293-FLAG-OATP1B1 cells. 
Coimmunofluorescence staining of FLAG-OATP1B1 (red) and LAMP-2 (green) was 
performed in HEK293-FLAG-OATP1B1 cells treated with vehicle CTL or 25 μM CQ for 2 
and 5 h as described in the Experimental Section. White arrow heads indicate the 
accumulation of FLAG-OATP1B1 inside the LAMP-2-positive vacuoles. Nuclei were 
counterstained with DAPI (blue). Images were taken using Olympus FV1000 confocal 
microscope. Representative images from the same experiments are shown (3 and 2 separate 
experiments for 2 h and 5 h treatment, respectively).
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Figure 4. 
Pretreatment effect and direct inhibition of CQ on OATP1B1-mediated transport. Cells were 
seeded at 1.1 × 105 cells/well in 24-well plates and cultured for 48 h (A, B, C, and E) or 72 
h. (D) Accumulation of [3H]E217G (1 μM, 2 min) or [3H]pitavastatin accumulation (1 μM, 
0.5 min) was determined in HEK293-OATP1B1 or -FLAG-OATP1B1 cells, as indicated in 
the figures. (A) Model-estimated fold change and associated SE in [3H]E217G accumulation 
vs CTL treatment in HEK293-OATP1B1 cells at each indicated pretreatment concentration 
and time (pre-incubation). (B) Model-estimated fold change and associated SE in 
[3H]pitavastatin accumulation vs CTL treatment in HEK293-OATP1B1 cells at each 
indicated pretreatment concentration and time (pre-incubation). (C) Model-estimated fold 
change and associated SE in [3H]E217G accumulation vs CTL treatment in HEK293-FLAG-
OATP1B1 cells at each indicated pretreatment concentration and time (pre-incubation). (D) 
Model-estimated fold change and associated SE in [3H]E217G accumulation in the presence 
of 5–100 μM CQ or 25 μM rifampicin (Rif) vs CTL in HEK293-OATP1B1 cells without CQ 
pretreatment (co-incubation). (E) Model-estimated fold change and associated SE in 
[3H]E217G accumulation vs co-incubation control. Following pretreatment in culture 
medium containing 100 μM CQ (pre+co-incubation) or vehicle control (co-incubation) for 5 
h, HEK293-OATP1B1 cells were rinsed three times with HBSS, and the [3H]E217G 
accumulation was determined in the presence of 100 μM CQ. A generalized linear mixed 
model as described in the Experimental Section was fit to data in A–E (n = 3 in triplicate for 
all panels of A–E). To account for multiple comparisons, p-values were adjusted based on 
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Bonferroni's method. * indicates a statistically significant difference (adjusted p < 0.05) vs 
CTL.
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Figure 5. 
Effects of monensin and bafilomycin A1 on OATP1B1-mediated [3H]E217G transport. 
HEK293-OATP1B1 were seeded at 1.1 × 105 cells/well in 24-well plates for up to 72 h. (A) 
Model-estimated fold change and associated SE in [3H]E217G accumulation vs CTL at each 
indicated monensin (5 μM) pretreatment time. (B) Model-estimated fold change and 
associated SE in [3H]E217G accumulation vs CTL at each indicated bafilomycin A1 (0.5 
μM) pretreatment time. A generalized linear mixed model as described in the Experimental 
Section was fit to data (n = 3 in triplicate for both A and B). * indicates a statistically 
significant difference (p < 0.05) vs CTL.
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Figure 6. 
Effects of CQ on OATP1B1-mediated [3H]E217G transport after prolonged treatment in 
HEK293-OATP1B1 cells. HEK293-OATP1B1 cells were seeded at 0.8 × 105 cells/well in 
24-well plates, and cultured for 48 h prior to treatment. Cells were preincubated with CQ-
free (CTL) or 25 μM CQ-containing medium for 2 h. At the end of pre-incubation, the 
culture medium was removed. CTL medium preincubated cells were cultured in CQ-free 
medium (CTL, black bar) and 25 μM CQ-preincubated cells were cultured in medium 
containing 1.5 μM CQ (grey bar), for indicated times up to 24 h. [3H]E217G accumulation 
(1 μM, 2 min) was determined at indicated time points (n = 4 in triplicate). Fold change and 
SE in [3H]E217G accumulation vs CTL at each indicated time points were estimated by 
generalized linear mixed models, as described in the Experimental Section. * indicates a 
statistically significant difference (p < 0.05) vs CTL.
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Figure 7. 
Effect of CQ pretreatment on the accumulation of [3H]pitavastatin in human SCH. (A) 
Time-dependent accumulation of [3H]pitavastatin (1 μM) in human SCH. Data represent the 
mean ± SD in triplicate from a single hepatocyte donor. (B) Model-estimated fold change 
and associated SE in [3H]pitavastatin accumulation vs CTL in human SCH pretreated with 
10 μM CQ or CTL for 5 h. Following pretreatment in culture medium containing CQ (10 
μM) or control, human SCH were rinsed three times with HBSS, and [3H]pitavastatin 
accumulation (1 μM, 0.5 min) was determined. Fold change and SE were estimated by a 
generalized linear mixed model, as described in the Experimental Section (n = 3 in 
triplicate). * indicates a statistically significant difference (p < 0.05) vs CTL.
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Figure 8. 
Effects of CQ on kinetic parameters of OATP1B1-mediated [3H]E217G transport. HEK293-
OATP1B1 and -Mock cells were seeded at 1.1 × 105 cells/well in 24-well plates and were 
cultured for 48 h prior to experiment. The concentration-dependent accumulation of 
[3H]E217G (0.1–40 μM, 2 min) was determined in HEK293-OATP1B1 and -Mock cells 
pretreated with CTL or CQ (25 μM, 2 h). Values of [3H]E217G accumulation in Mock cells 
were subtracted from those in HEK293-OATP1B1 cells. Vmax and Km values were 
determined as described in the Experimental Section. Solid and dashed lines represent the 
best fits of the Michaelis–Menten equation to the data of CTL (black circles) and CQ (25 
μM, 2 h) pretreatment (white circles), respectively. Representative graph of three 
independent experiments in triplicate is shown. Student's t test was conducted to compare 
the Vmax and Km values between CQ and CTL pretreatment. * indicates a statistically 
significant difference (p < 0.05; CQvs CTL).
Alam et al. Page 29
Mol Pharm. Author manuscript; available in PMC 2016 August 02.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Alam et al. Page 30
Ta
bl
e 
1
D
em
og
ra
ph
ic
s o
f H
um
an
 H
ep
at
oc
yt
e 
D
on
or
s
do
no
rs
a
ge
ge
nd
er
ra
ce
BM
Ia
sm
o
ki
ng
a
lc
oh
ol
 u
se
ex
pe
ri
m
en
ts
G
C4
00
8
69
M
Ca
uc
as
ia
n
24
.7
n
o
n
o
Fi
gu
re
s 2
C,
 7
B
H
U
M
 4
05
9
17
F
Ca
uc
as
ia
n
25
.5
n
o
n
o
Fi
gu
re
 7
B
H
U
M
 4
08
9
36
M
Ca
uc
as
ia
n
30
n
o
n
o
Fi
gu
re
 7
A
H
U
M
 4
11
0
56
M
Ca
uc
as
ia
n
26
ye
s
8–
10
 b
ee
rs
/w
ee
k
Fi
gu
re
 7
B
H
U
M
 4
13
0
64
M
A
fri
ca
n 
A
m
er
ic
an
23
.6
qu
it 
3 
m
on
th
s a
go
n
o
n
e 
re
po
rte
d
Fi
gu
re
 2
C
H
U
M
 4
14
0
21
M
Ca
uc
as
ia
n
32
ye
s
ra
re
Fi
gu
re
 2
C
a B
od
y 
m
as
s i
nd
ex
.
Mol Pharm. Author manuscript; available in PMC 2016 August 02.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Alam et al. Page 31
Table 2
Estimation of CQ Maximum Unbound Concentration at the Inlet to the Liver (Iu,in,max)
variable
dose of CQ (mg)a 19148 30039 60049
Cmax (μM) 0.72–12.1848 0.2439 1.249
Iu,in,maxbb (μM) 18.3–23.4 28.2 56.8
aCQ doses were converted to CQ base.
b
Estimated on the basis of eq 1.
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